Sophiris says it’s ready to get back on track with lead drug after patient death — but questions linger
Sophiris’ shares $SPHS took a beating two months ago when the biotech disclosed that a patient died on the same day of a second …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
